Lunesta Crenessity, supermodel and friend of Bono
Lunesta Crenessity, poet laureate of the Dyson sphere
December 1, 2025 at 12:13 PM
Lunesta Crenessity, supermodel and friend of Bono
Lunesta Crenessity, poet laureate of the Dyson sphere
December 1, 2025 at 11:39 AM
Lunesta Crenessity, poet laureate of the Dyson sphere
Neurocrine Biosciences Unveils Two-Year CRENESSITY Data at ENDO 2026: Promising Cardiometabolic Improvements#USA#Chicago#Crenessity#Neurocrine_Biosciences#Congenital_Adrenal_Hyperplasia
Neurocrine Biosciences Unveils Two-Year CRENESSITY Data at ENDO 2026: Promising Cardiometabolic Improvements
Neurocrine Biosciences presented new data showcasing significant cardiometabolic improvements over two years with CRENESSITY in adults with CAH at ENDO 2026.
third-news.com
June 15, 2026 at 12:37 PM
Neurocrine Biosciences Unveils Two-Year CRENESSITY Data at ENDO 2026: Promising Cardiometabolic Improvements#USA#Chicago#Crenessity#Neurocrine_Biosciences#Congenital_Adrenal_Hyperplasia
Neurocrine Biosciences Launches CRENESSITY™ for Classic CAH Treatment in the U.S.#United_States#San_Diego#Crenessity#CAH#Neurocrine
Neurocrine Biosciences Launches CRENESSITY™ for Classic CAH Treatment in the U.S.
Neurocrine Biosciences has launched CRENESSITY™, a groundbreaking treatment for classic congenital adrenal hyperplasia (CAH), now available in the U.S. for eligible patients.
third-news.com
December 20, 2024 at 1:15 PM
Neurocrine Biosciences Launches CRENESSITY™ for Classic CAH Treatment in the U.S.#United_States#San_Diego#Crenessity#CAH#Neurocrine
Each year I invariably look up the FDA Novel Drug Approval list to have a laugh at the names, and I hoped this year’s list would help cut some gloom… but 2025 is pretty weak, especially compared to 2024 when we had Crenessity, Unloxcyt, Flyrcado *and* Lazcluze. And who can forget 2023’s Beyfortus.
September 4, 2025 at 3:20 AM
Each year I invariably look up the FDA Novel Drug Approval list to have a laugh at the names, and I hoped this year’s list would help cut some gloom… but 2025 is pretty weak, especially compared to 2024 when we had Crenessity, Unloxcyt, Flyrcado *and* Lazcluze. And who can forget 2023’s Beyfortus.
Neurocrine Biosciences Reveals Encouraging Data on CRENESSITY® for Pediatric CAH Patients at ENDO 2026#USA#Chicago#Neurocrine_Biosciences#CAHtalyst_Study#CRF1_Antagonist
Neurocrine Biosciences Reveals Encouraging Data on CRENESSITY® for Pediatric CAH Patients at ENDO 2026
New findings from Neurocrine Biosciences demonstrate that CRENESSITY® significantly improves growth measures in pediatric patients with classic congenital adrenal hyperplasia.
third-news.com
June 15, 2026 at 12:49 PM
Neurocrine Biosciences Reveals Encouraging Data on CRENESSITY® for Pediatric CAH Patients at ENDO 2026#USA#Chicago#Neurocrine_Biosciences#CAHtalyst_Study#CRF1_Antagonist
Does anyone have a sense of whether the set of Englishy drug trade names is only finitely countable?
"Crenessity" (crinecerfont) is kind of painful to what's left of my editorial eye.
"Crenessity" (crinecerfont) is kind of painful to what's left of my editorial eye.
May 27, 2026 at 7:32 PM
Does anyone have a sense of whether the set of Englishy drug trade names is only finitely countable?
"Crenessity" (crinecerfont) is kind of painful to what's left of my editorial eye.
"Crenessity" (crinecerfont) is kind of painful to what's left of my editorial eye.
#NBIX Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-reports-second-quarter-2026-financial-kk792o4ervhx.html
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-reports-second-quarter-2026-financial-kk792o4ervhx.html
Neurocrine Completes $2.9B Soleno Deal, Adds PWS Therapy
INGREZZA sales reached $716 million and CRENESSITY $184 million in Q2; Neurocrine raised 2026 INGREZZA guidance to $2.825-$2.875 billion.
www.stocktitan.net
July 30, 2026 at 8:01 PM
#NBIX Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-reports-second-quarter-2026-financial-kk792o4ervhx.html
https://www.stocktitan.net/news/NBIX/neurocrine-biosciences-reports-second-quarter-2026-financial-kk792o4ervhx.html
Neurocrine Biosciences Launches Strong Growth in Q2 2026 With Major Milestones Ahead#USA#San_Diego#Crenessity#Neurocrine#INGREZZA
Neurocrine Biosciences Launches Strong Growth in Q2 2026 With Major Milestones Ahead
Neurocrine Biosciences reports an impressive revenue growth in Q2 2026, bolstered by product sales and strategic acquisitions, showcasing its commitment to innovative treatments.
third-news.com
July 30, 2026 at 8:06 PM
Neurocrine Biosciences Launches Strong Growth in Q2 2026 With Major Milestones Ahead#USA#San_Diego#Crenessity#Neurocrine#INGREZZA
Neurocrine Q1 Earnings Soar Past Estimates as CRENESSITY Sales Explode, Driving 187% Profit Growth https://signalbloom.ai/news/NBIX/neurocrine-q1-earnings-soar-past-estimates-as-crenessity-sales-explode-driving-187-profit-growth $NBIX #Earnings via @signalbloom.ai
May 5, 2026 at 8:06 PM
Neurocrine Q1 Earnings Soar Past Estimates as CRENESSITY Sales Explode, Driving 187% Profit Growth https://signalbloom.ai/news/NBIX/neurocrine-q1-earnings-soar-past-estimates-as-crenessity-sales-explode-driving-187-profit-growth $NBIX #Earnings via @signalbloom.ai
Neurocrine Revenue Surges 28% on CRENESSITY Launch, But High Costs Squeeze Profits https://signalbloom.ai/news/NBIX/neurocrine-revenue-surges-28-on-crenessity-launch-but-high-costs-squeeze-profits $NBIX #Earnings via @signalbloom.ai
February 11, 2026 at 9:05 PM
Neurocrine Revenue Surges 28% on CRENESSITY Launch, But High Costs Squeeze Profits https://signalbloom.ai/news/NBIX/neurocrine-revenue-surges-28-on-crenessity-launch-but-high-costs-squeeze-profits $NBIX #Earnings via @signalbloom.ai
Feed: "MashupMD"
By: Mashup MD on Sunday, June 14, 2026
By: Mashup MD on Sunday, June 14, 2026
Crenessity has positive effects on weight, insulin resistance, bone age in CAH at 2 years
Up-to-date medical news aggregated from trusted medical associations, journals, physicians and news outlets from around the world.
www.mashupmd.com
June 14, 2026 at 9:35 PM
Feed: "MashupMD"
By: Mashup MD on Sunday, June 14, 2026
By: Mashup MD on Sunday, June 14, 2026
Feed: "MedCity News"
By: Frank Vinluan on Monday, April 6, 2026
By: Frank Vinluan on Monday, April 6, 2026
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug
Soleno Therapeutics brings Neurocrine Biosciences Vykat XR, a drug commercialized for treating the rare genetic disease Prader-Willi syndrome. This blockbuster prospect complements Crenessity, a Neurocrine drug approved for treating a rare endocrine disorder called congenital adrenal hyperplasia.
medcitynews.com
April 7, 2026 at 5:36 PM
Feed: "MedCity News"
By: Frank Vinluan on Monday, April 6, 2026
By: Frank Vinluan on Monday, April 6, 2026
Feed: "Clinical Trials Arena"
By: gullapalli on Tuesday, July 15, 2025
By: gullapalli on Tuesday, July 15, 2025
Neurocrine shares new one-year data from trial of Crenessity for CAH
Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity for classic CAH.
www.clinicaltrialsarena.com
July 16, 2025 at 1:51 AM
Feed: "Clinical Trials Arena"
By: gullapalli on Tuesday, July 15, 2025
By: gullapalli on Tuesday, July 15, 2025
Feed: "Business-News-Today.com"
By: Pallavi Madhiraju on Tuesday, July 15, 2025
By: Pallavi Madhiraju on Tuesday, July 15, 2025
Neurocrine Biosciences’ one-year CAHtalyst phase 3 data shows sustained weight and insulin-resistance benefits in CAH patients
Neurocrine Biosciences’ CRENESSITY Phase 3 data shows strong weight and metabolic benefits in CAH—see what this means for NBIX stock and future sales.
business-news-today.com
July 15, 2025 at 6:07 AM
Feed: "Business-News-Today.com"
By: Pallavi Madhiraju on Tuesday, July 15, 2025
By: Pallavi Madhiraju on Tuesday, July 15, 2025
